Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the overall safety and general tolerability
of extended release triamcinolone acetate (TA-ER/FX006) in patient with rotator cuff disease.
The study will enroll 65 patients, aged 40-75 years old, in a longitudinal case series level
IV study using extended release triamcinolone to treat shoulder pain from rotator cuff
disease. Inclusion criteria will be shoulder pain without a history of trauma and physical
exam consistent with rotator cuff tendinitis, impingement syndrome or rotator cuff tear.